WEKO3
AND
アイテム
{"_buckets": {"deposit": "ee3838e9-d245-488f-bc0e-ced719781211"}, "_deposit": {"id": "8243", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "8243"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00008243"}, "item_7_alternative_title_1": {"attribute_name": "\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_alternative_title": "Phase I Dose Finding Study of the Addition of Docetaxel to Gefitinib Beyond Progressive Disease"}]}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "423", "bibliographicPageStart": "413", "bibliographicVolumeNumber": "131", "bibliographic_titles": [{"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c"}, {"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "\u3010\u76ee\u7684\u3011\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3067\u75c5\u52e2\u6291\u5236\u5f8c\u9032\u884c\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\uff0c\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u7d99\u7d9a\u4e0b\u3067\u306e\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u4f75\u7528\u7642\u6cd5\u306e\u6700\u5927\u8010\u7528\u91cf\uff08MTD\uff09\u304a\u3088\u3073\u63a8\u5968\u7528\u91cf\uff08RD\uff09\u3092\u6c7a\u5b9a\u3059\u308b\u3053\u3068\uff0e\u3010\u65b9\u6cd5\u3011\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3067\u6cbb\u7642\u52b9\u679c\u3092\u8a8d\u3081\u305f\u5f8c\u306b\u75c5\u52e2\u304c\u9032\u884c\u3057\u305fPS0-1\uff0c20\u6b73\u4ee5\u4e0a\u306e\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c7\u4f8b\u306b\u5bfe\u3057\u3066\uff0c\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\uff08250mg/day\uff09\u306f\u9023\u65e5\u6295\u4e0e\u3067\u7d99\u7d9a\u3057\uff0c\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb(level 1\uff1a50mg/m^2\uff0c\u540c2\uff1a60mg/m^2\uff0c\u540c3\uff1a70mg/m^2)\u3092day1\u306b\u6295\u4e0e\u30573\u9031\u9593\u30671\u30b3\u30fc\u30b9\u3068\u3057\u305f\uff0e\u7528\u91cf\u5236\u9650\u6bd2\u6027\uff08DLT\uff09\u306f4\u65e5\u4ee5\u4e0a\u7d9a\u304fgrade4\u306e\u597d\u4e2d\u7403\u6e1b\u5c11\uff0cgrade4\u306e\u8840\u5c0f\u677f\u6e1b\u5c11\uff0c2\u9031\u9593\u3092\u8d85\u3048\u308b\u6295\u4e0e\u306e\u5ef6\u671f\uff0cgrade3\u4ee5\u4e0a\u306e\u975e\u8840\u6db2\u6bd2\u6027\u3068\u3057\uff0c1\u30b3\u30fc\u30b9\u76ee\u3067\u8a55\u4fa1\u3057\u305f\uff0e\u3010\u7d50\u679c\u3011Level1\u306b4\u4f8b\uff0clevel2\u306b5\u4f8b\uff0clevel3\u306b5\u4f8b\u306e\u8a0814\u4f8b\u304c\u767b\u9332\u3055\u308c\u305f\uff0e\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u306e\u6295\u4e0e\u30b3\u30fc\u30b9\u6570\u4e2d\u592e\u5024\u306f4\u30b3\u30fc\u30b9\u3067\u3042\u3063\u305f\uff0eDLT\u306flevel2\u306b1\u4f8b\uff084\u65e5\u9593\u4ee5\u4e0a\u306egrade4\u306e\u597d\u4e2d\u7403\u6e1b\u5c11\uff09\uff0clevel3\u306b1\u4f8b\uff084\u65e5\u9593\u4ee5\u4e0a\u306egrade4\u306e\u597d\u4e2d\u7403\u6e1b\u5c11\u3068\u767a\u71b1\u6027\u597d\u4e2d\u7403\u6e1b\u5c11\u75c7\u306e\u4f75\u767a\uff09\u8a8d\u3081\u3089\u308c\u305f\uff0e\u8a55\u4fa1\u53ef\u80fd\u75c7\u4f8b\u306b\u304a\u3051\u308b\u594f\u52b9\u5272\u5408\u306f43\uff05\uff0c\u75c5\u52e2\u5236\u5fa1\u7387\u306f100\uff05\u3067\u3042\u3063\u305f\uff0eLevel3\uff08\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb70mg/m^2\uff09\u306b\u304a\u3051\u308bDLT\u306f5\u4f8b\u4e2d1\u4f8b\u3067\u3042\u3063\u305f\u304c\uff0c\u5168\u4f8b\u3067grade4\u306e\u597d\u4e2d\u7403\u6e1b\u5c11\u304c\u51fa\u73fe\u3057G-CSF\u306e\u6295\u4e0e\u3092\u5fc5\u8981\u3068\u3057\u305f\u3053\u3068\u306a\u3069\u304b\u3089\uff0c \u30ec\u30d9\u30eb3\u3092MTD\u3068\u3057\u305f\uff0eRD\u3068\u6c7a\u5b9a\u3055\u308c\u305flevel2\u306e\u594f\u52b9\u5272\u5408\u306f40%\u3067\u3042\u3063\u305f\uff0e\u3010\u7d50\u8ad6\u3011\u672c\u6cbb\u7642\u6cd5\u306e\u5fcd\u5bb9\u6027\u306f\u826f\u597d\u3067\u3042\u308a\uff0c\u6297\u816b\u760d\u52b9\u679c\u304c\u793a\u5506\u3055\u308c\u305f\uff0e", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "\u8457\u8005\u5225\u540d", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "57867", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Ota, Takeshi"}]}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u65b0\u6f5f\u533b\u5b66\u4f1a"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u592a\u7530, \u6bc5"}], "nameIdentifiers": [{"nameIdentifier": "57866", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "131(7)_413-423.pdf", "filesize": [{"value": "2.9 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2900000.0, "url": {"label": "131(7)_413-423.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/8243/files/131(7)_413-423.pdf"}, "version_id": "c7d77c65-f59c-459e-84f5-3ade4bf2a911"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "\u975e\u5c0f\u7d30\u80de\u80ba\u764c", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u7b2c\u2160\u76f8\u81e8\u5e8a\u8a66\u9a13", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3067\u75c5\u52e2\u6291\u5236\u5f8c\u9032\u884c\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u7d99\u7d9a\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u4f75\u7528\u7642\u6cd5\u306e\u7b2c\u2160\u76f8\u8a66\u9a13", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3067\u75c5\u52e2\u6291\u5236\u5f8c\u9032\u884c\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u7d99\u7d9a\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u4f75\u7528\u7642\u6cd5\u306e\u7b2c\u2160\u76f8\u8a66\u9a13"}, {"subitem_title": "\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3067\u75c5\u52e2\u6291\u5236\u5f8c\u9032\u884c\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u7d99\u7d9a\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u4f75\u7528\u7642\u6cd5\u306e\u7b2c\u2160\u76f8\u8a66\u9a13", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/538/885"], "permalink_uri": "http://hdl.handle.net/10191/49637", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2018-02-28"}, "publish_date": "2018-02-28", "publish_status": "0", "recid": "8243", "relation": {}, "relation_version_is_last": true, "title": ["\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3067\u75c5\u52e2\u6291\u5236\u5f8c\u9032\u884c\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u7d99\u7d9a\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u4f75\u7528\u7642\u6cd5\u306e\u7b2c\u2160\u76f8\u8a66\u9a13"], "weko_shared_id": null}
ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験
http://hdl.handle.net/10191/49637
a6a1f0dc-bf26-4d14-88fc-e6b09207f4da
| 名前 / ファイル | ライセンス | アクション | |
|---|---|---|---|
131(7)_413-423.pdf (2.9 MB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-02-28 | |||||
| タイトル | ||||||
| タイトル | ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験 | |||||
| タイトル | ||||||
| 言語 | en | |||||
| タイトル | ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 非小細胞肺癌 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | ゲフィチニブ | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | ドセタキセル | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 第Ⅰ相臨床試験 | |||||
| 資源タイプ | ||||||
| 資源 | http://purl.org/coar/resource_type/c_6501 | |||||
| タイプ | departmental bulletin paper | |||||
| その他のタイトル | ||||||
| その他のタイトル | Phase I Dose Finding Study of the Addition of Docetaxel to Gefitinib Beyond Progressive Disease | |||||
| 著者 |
太田, 毅
× 太田, 毅 |
|||||
| 著者別名 | ||||||
| 識別子 | ||||||
| 識別子 | 57867 | |||||
| 識別子Scheme | WEKO | |||||
| 姓名 | ||||||
| 姓名 | Ota, Takeshi | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | 【目的】ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対する，ゲフィチニブ継続下でのドセタキセル併用療法の最大耐用量（MTD）および推奨用量（RD）を決定すること．【方法】ゲフィチニブで治療効果を認めた後に病勢が進行したPS0-1，20歳以上の非小細胞肺癌症例に対して，ゲフィチニブ（250mg/day）は連日投与で継続し，ドセタキセル(level 1：50mg/m^2，同2：60mg/m^2，同3：70mg/m^2)をday1に投与し3週間で1コースとした．用量制限毒性（DLT）は4日以上続くgrade4の好中球減少，grade4の血小板減少，2週間を超える投与の延期，grade3以上の非血液毒性とし，1コース目で評価した．【結果】Level1に4例，level2に5例，level3に5例の計14例が登録された．ドセタキセルの投与コース数中央値は4コースであった．DLTはlevel2に1例（4日間以上のgrade4の好中球減少），level3に1例（4日間以上のgrade4の好中球減少と発熱性好中球減少症の併発）認められた．評価可能症例における奏効割合は43％，病勢制御率は100％であった．Level3（ドセタキセル70mg/m^2）におけるDLTは5例中1例であったが，全例でgrade4の好中球減少が出現しG-CSFの投与を必要としたことなどから， レベル3をMTDとした．RDと決定されたlevel2の奏効割合は40%であった．【結論】本治療法の忍容性は良好であり，抗腫瘍効果が示唆された． | |||||
| 書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 131, 号 7, p. 413-423, 発行日 2017-07 |
|||||
| 出版者 | ||||||
| 出版者 | 新潟医学会 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00290440 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN00182415 | |||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
